QPPV.COM KNOWLEDGE ASSESSMENT

Carbidopa/Levodopa: Vitamin B6 Deficiency, Refractory Seizures and Pharmacovigilance

Test your understanding of the concepts covered by Carbidopa/Levodopa: Vitamin B6 Deficiency, Refractory Seizures and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 What should a multinational safety team do with the FDA warning?

Apply the US label wording immediately worldwide. Ignore it outside the United States. Assess the US action and compare it separately with local labels and requirements. Treat it as a new global indication.

Question 2 of 10 Which record best supports a traceable signal decision?

A final conclusion without methods or data cut. A raw case count only. A list of labels without case review. The question, data cut, case definition, search, deduplication, limitations, rationale and reassessment owner.

Question 3 of 10 What is the key distinction among modern formulations?

They share no active pharmacology. They all use the same route and dosing schedule. Only oral formulations contain levodopa. They differ in route, delivery and product details even when they share the carbidopa/levodopa pathway.

Question 4 of 10 What did FDA announce on 20 March 2026?

Withdrawal of all oral carbidopa/levodopa products. A new indication for treatment of vitamin B6 deficiency. A class-wide required warning revision concerning B6 deficiency and associated seizures. A boxed warning limited to the injectable product.

Question 5 of 10 Which treatment-response pattern did FDA report?

Seizures resolved in all nine cases reported to have received vitamin B6 supplementation. Seizures resolved in all 14 cases without treatment. Only patients receiving entacapone responded to vitamin B6. Vitamin B6 worsened all reported seizures.

Question 6 of 10 Why did FDA extend its concern across products that deliver carbidopa/levodopa?

All products have identical dosage and exposure. Every route had the same number of reported cases. The labels were harmonised by manufacturers without FDA review. Shared pharmacology supported biological plausibility despite product-specific evidence differences.

Question 7 of 10 What does the >1,000 mg/day observation establish?

It is a validated threshold below which the risk is absent. It describes the reviewed cases but does not define a universal safety threshold. It proves that all patients at higher doses will develop seizures. It establishes incidence among high-dose users.

Question 8 of 10 What is the correct relation between the older pyridoxine interaction and the 2026 warning?

They are distinct: carbidopa inhibits pyridoxine’s effect on peripheral levodopa decarboxylation, while FDA warns of possible B6 deficiency during combination treatment. They prove vitamin B6 must never be given with any Parkinson’s medicine. The interaction shows that B6 deficiency cannot occur with carbidopa. The 2026 warning applies only to levodopa monotherapy.

Question 9 of 10 Which conclusion best reflects the two reported fatalities?

Both deaths establish a 14% fatality rate in all users. The deaths were unrelated to B6 because they occurred after treatment. Both patients had documented low B6 and poorly controlled seizures, but this small case set does not estimate mortality risk. FDA found no deaths in its review.

Question 10 of 10 How many cases did FDA identify in its safety review?

14, comprising 13 FDA postmarketing reports and one literature case. 14 clinical-trial cases from a prospective registry. 13 cases, all published in the literature. Nine cases, all involving injectable treatment.

QPPV.com

Carbidopa/Levodopa: Vitamin B6 Deficiency, Refractory Seizures and Pharmacovigilance

Cookie Settings